Galapagos BE0003818359

Overname van....Gilead....?

1. diederique 22 september 2016 21:19

   auteur info

   • diederique

     Lid sinds: 01 mrt 2004

     Laatste bezoek: 04 apr 2024

   • Aanbevelingen

     Ontvangen: 913

     Gegeven: 218

   •    Aantal posts: 8.547

   kan zomaar gebeuren...
   
   .....The latest idea? That the Dublin drugmaker may target Gilead, whose $107 billion market cap is quite a ways off
   of the heights it reached last year.
   
   www.fiercepharma.com/pharma/allergan-...
2. diederique 23 september 2016 00:25

   auteur info

   • diederique

     Lid sinds: 01 mrt 2004

     Laatste bezoek: 04 apr 2024

   • Aanbevelingen

     Ontvangen: 913

     Gegeven: 218

   •    Aantal posts: 8.547

   Will Gilead Make a Good Fit for Allergan?
   
   Allergen’s surprise interest emerged without any earlier indications of interest in companies focused on NASH or liver diseases. Given the backdrop of recent acquisitions, the market is abuzz with rumors about Gilead being the next potential target for Allergan.
   
   www.investopedia.com/news/will-gilead...
3. diederique 23 september 2016 21:54

   auteur info

   • diederique

     Lid sinds: 01 mrt 2004

     Laatste bezoek: 04 apr 2024

   • Aanbevelingen

     Ontvangen: 913

     Gegeven: 218

   •    Aantal posts: 8.547

   Allergan joins a growing field of companies intent on conquering NASH, which include Gilead Sciences Inc. GILD, -0.10% , Bristol-Myers Squibb Co. BMY, +0.23% , Intercept Pharmaceuticals Inc. ICPT, -2.42% , Galmed Pharmaecuticals Ltd. GLMD, -1.64% , Astra-Zeneca Plc AZN, -0.88% and Novartis AG NVS, -0.53% , among others, according to BioMedTracker.
   
   www.marketwatch.com/story/allergan-is...